Methods for treatment of bladder cancer
Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution is coated onto at least a portion of the internal cavity, and acts as a slow-release drug delivery system.
1. A method of treating urinary bladder cancer comprising:
a) obtaining a treatment solution consisting of:
(i) at least one anticancer agent,
(ii) at least one polymer,
(iii) water, and
(iv) optionally at least one of:
(a) an antibiotic or
(b) a halobacter bacterium;
b) administering the treatment solution directly to an internal wall of a urinary bladder of a human in need thereof;
c) coating at least a portion of the internal wall of the urinary bladder of the human with the treatment solution; and
d) stabilizing the treatment solution in the urinary bladder of the human without contact with urine.
2. The method of claim 1 , wherein the anticancer agent is selected from the group consisting of bacillus calmett-guerin, thiotepa, doxorubicin, halobacter, gemcitabine, mitomycin C, epirubicin, paclitaxel and any combination thereof.
3. The method of claim 2 , wherein the anticancer agent is gemcitabine.
4. The method of claim 1 , wherein the at least one polymer is at least one of:
at least one hydrophilic polymer or
at least one hydrophobic polymer.
5. The method of claim 1 , wherein the at least one polymer is at least one of glycolic acid, polylactic acid, polyurethanes, polyphosphazines, polycaprolactone, poly[bis(pcarboxyphenoxy) propaneanhydride], polyethylene glycol, trirnethylene carbonated and polymerizable acrylic ester, homopolymers and copolymers of delta-valerolactone, and p-dioxanone, copolymers of delta-valerolactone, and p-dioxanone and caprolactone, deltavalerolactone, and p-dioxanone cross-linked with bis-caprolactone, polyanhydrides, or polyvinylpyrrolidone.
6. The method of claim 5 , wherein the anticancer agent is gemcitabine and the at least one polymer is polyethylene glycol, polylactic acid, and trimethylene carbonated and polymerizable acrylic ester.